 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Apr 1 Calls Today's Calls |
| Call Details | |||
| ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation Tue, Apr 1, 2008, 4:30 pm Eastern
| |||
| About ISTA Pharmaceuticals, Inc. (NasdaqGM:ISTA) | Other Calls | ||
| ISTA Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, engages in the discovery, development, and marketing of therapies for inflammation, ocular pain, glaucoma, allergy, dry eye, vitreous hemorrhage, and diabetic retinopathy in the United States. It offers Xibrom for the treatment of inflammation and pain following cataract surgery; Istalol for the treatment of glaucoma; and Vitrase for use as a spreading agent. The company’s products include T-Pred for the treatment of steroid-responsive inflammatory ocular conditions where risk of bacterial infection exists; Bepotastine ophthalmic solution, a second Phase III clinical trial product for allergic conjunctivitis; Bepotastine nasal for the treatment of allergic rhinitis; Ecabet Sodium, a Phase IIb clinical trial product for the treatment of dry eye syndrome; and Strong Steroid for the treatment of ocular inflammation and allergy. Its products also include a Xibrom/steroid combination product to treat inflammation; iganidipine to enhance ocular nerve blood flow; and a new formulation of latanoprost for the treatment of glaucoma. ISTA Pharmaceuticals sells its products primarily to drug wholesalers, retailers, and distributors, including chain drug stores, hospitals, clinics, government agencies, and managed healthcare providers. The company was founded in 1992 as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in 2000. ISTA Pharmaceuticals is headquartered in Irvine, California. | |||
More Info: | |||
